Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

Rhea-AI Summary

Pelthos Therapeutics (NYSE American: PTHS) announced that CEO Scott Plesha will attend one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston. Investors should contact their Piper Sandler representative to arrange meetings.

Market Context

This announcement highlights Pelthos’s continued engagement with institutional investors through one...

Analysis

This announcement highlights Pelthos’s continued engagement with institutional investors through one-on-one meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026. It follows recent clinical, earnings, and financing milestones and a pattern of conference participation to raise visibility. Investors may track how this outreach complements the existing $200,000,000 effective shelf registration filed on 2026-02-02 and recent leadership and insider-activity disclosures when assessing the company’s funding and execution trajectory.

Key Figures

Conference date: April 16, 2026 Announcement date: April 14, 2026

2 metrics

Conference date April 16, 2026 Piper Sandler Spring Biopharma Symposium one-on-one meetings

Announcement date April 14, 2026 Press release publication date

Historical Context

5 past events · Latest: Mar 31 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 31	Clinical trial start	Positive	+0.1%	First patient dosed in Phase 1b/2a CT2000 eye pain trial.
Mar 19	Earnings and financing	Positive	-4.6%	Q4 and full-year 2025 results with revenue growth and new financings.
Mar 09	Earnings date notice	Neutral	-0.3%	Announcement of date and call details for Q4 and 2025 results.
Feb 23	Investor conference	Positive	+5.0%	CEO presentation and one-on-ones at Oppenheimer healthcare conference.
Jan 13	Debt financing	Positive	-1.3%	Up to $50M Horizon term loan to fund commercialization and launches.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

PTHS has shown mixed reactions to news: positive responses to some conference events, but negative or flat moves around financing and earnings updates.

Recent Company History

Over recent months, Pelthos has combined financing, clinical, and commercial milestones. A Jan 13 term loan facility supported launches of ZELSUVMI and acquired assets. On Mar 19, full-year 2025 results highlighted early revenue traction and additional funding, followed by modest share pressure. Clinical progress continued with first patient dosing in a Phase 1b/2a CT2000 trial on Mar 31. The current Piper Sandler investor meetings echo the Feb 23 Oppenheimer appearance, extending an active investor-relations cadence.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DURHAM, N.C., April 14, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that CEO Scott Plesha will participate in one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston. Investors interested in arranging one-on-one meetings should contact their Piper Sandler representative.

About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI™ (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat Molluscum contagiosum. The company’s portfolio of assets includes Xepi® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and Xeglyze® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Contacts
Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072

FAQ

When will Pelthos Therapeutics (PTHS) participate in the Piper Sandler Spring Biopharma Symposium?

Pelthos will participate on April 16, 2026 in Boston with one-on-one investor meetings. According to Pelthos, CEO Scott Plesha will be available for investor meetings coordinated through Piper Sandler representatives.

How can investors schedule one-on-one meetings with PTHS CEO Scott Plesha at the April 16, 2026 symposium?

Investors should contact their Piper Sandler representative to arrange meetings at the symposium. According to Pelthos, meeting requests are handled through Piper Sandler’s scheduling process for the April 16, 2026 Boston event.

Will Pelthos Therapeutics (PTHS) hold a public presentation at the Piper Sandler Spring Biopharma Symposium on April 16, 2026?

No public presentation was announced; the company scheduled one-on-one investor meetings only. According to Pelthos, CEO Scott Plesha will participate in private investor meetings rather than a public symposium presentation.

Who from Pelthos Therapeutics will represent the company at the Piper Sandler symposium (PTHS) on April 16, 2026?

CEO Scott Plesha will represent Pelthos at the event for one-on-one investor meetings. According to Pelthos, he will be available in Boston on April 16, 2026 through meetings arranged by Piper Sandler.

Where will Pelthos Therapeutics (PTHS) meetings take place during the Piper Sandler Spring Biopharma Symposium?

Meetings are scheduled at the Piper Sandler Spring Biopharma Symposium in Boston on April 16, 2026. According to Pelthos, investors must coordinate with their Piper Sandler representative to confirm exact meeting times and locations.